107 related articles for article (PubMed ID: 30315343)
1. Atypical bortezomib-induced neutrophilic dermatosis.
Lescoat A; Dupuy A; Belhomme N; Stock N; Sebillot M; Decaux O; Jégo P; Droitcourt C
Ann Hematol; 2019 May; 98(5):1315-1316. PubMed ID: 30315343
[No Abstract] [Full Text] [Related]
2. Bortezomib-induced histiocytoid Sweet syndrome.
Murase JE; Wu JJ; Theate I; Cole GW; Barr RJ; Dyson SW
J Am Acad Dermatol; 2009 Mar; 60(3):496-7. PubMed ID: 19231647
[TBL] [Abstract][Full Text] [Related]
3. Histiocytoid sweet syndrome related to bortezomib: A mimicker of cutaneous infiltration by myeloma.
Llamas-Velasco M; Concha-Garzón MJ; Fraga J; Aragüés M
Indian J Dermatol Venereol Leprol; 2015; 81(3):305-6. PubMed ID: 25784226
[No Abstract] [Full Text] [Related]
4. [Bortezomib-induced acute neutrophilic dermatosis].
Tanguy-Schmidt A; Avenel-Audran M; Croué A; Lissandre S; Dib M; Zidane-Marinnes M; Moles MP; Hunault-Berger M
Ann Dermatol Venereol; 2009 May; 136(5):443-6. PubMed ID: 19442803
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib-induced Sweet's syndrome.
Van Regenmortel N; Van de Voorde K; De Raeve H; Rombouts S; Van de Velde A; Lambert J; Schroyens W
Haematologica; 2005 Dec; 90(12 Suppl):ECR43. PubMed ID: 16464758
[TBL] [Abstract][Full Text] [Related]
6. Neutrophilic dermatosis complicating lenalidomide therapy.
Thieu KP; Rosenbach M; Xu X; Kist JM
J Am Acad Dermatol; 2009 Oct; 61(4):709-10. PubMed ID: 19577327
[TBL] [Abstract][Full Text] [Related]
7. Distinct variant of Sweet's syndrome: bortezomib-induced histiocytoid Sweet's syndrome in a patient with multiple myeloma.
Kim JS; Roh HS; Lee JW; Lee MW; Yu HJ
Int J Dermatol; 2012 Dec; 51(12):1491-3. PubMed ID: 22998496
[No Abstract] [Full Text] [Related]
8. Sweet-like syndrome induced by bortezomib.
Kolb-Mäurer A; Kneitz H; Goebeler M
J Dtsch Dermatol Ges; 2013 Dec; 11(12):1200-2. PubMed ID: 23905772
[No Abstract] [Full Text] [Related]
9. Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants.
Jethava YS; Mitchell A; Epstein J; Zangari M; Yaccoby S; Tian E; Waheed S; Khan R; Papanikolaou X; Grazziutti M; Cottler-Fox M; Petty N; Steward D; Panozzo S; Bailey C; Hoering A; Crowley J; Sawyer J; Morgan G; Barlogie B; van Rhee F
Clin Cancer Res; 2017 Jun; 23(11):2665-2672. PubMed ID: 27810902
[No Abstract] [Full Text] [Related]
10. Bortezomib-induced Sweet's syndrome confirmed by rechallenge.
Zobniw CM; Saad SA; Kostoff D; Barthel BG
Pharmacotherapy; 2014; 34(4):e18-21. PubMed ID: 24338786
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study.
Grammatico S; Bringhen S; Vozella F; Siniscalchi A; Boccadoro M; Petrucci MT
Leuk Lymphoma; 2017 Nov; 58(11):2738-2740. PubMed ID: 28402163
[No Abstract] [Full Text] [Related]
12. [Bortezomib-induced eruption: Sweet syndrome? Two case reports].
Thuillier D; Lenglet A; Chaby G; Royer R; Vaida I; Viseux V; Dadban A; Billet A; Christophe O; Chatelain D; Marolleau JP; Lok C; Damaj G
Ann Dermatol Venereol; 2009 May; 136(5):427-30. PubMed ID: 19442799
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib-induced Sweet syndrome.
Knoops L; Jacquemain A; Tennstedt D; Theate I; Ferrant A; Van den Neste E
Br J Haematol; 2005 Oct; 131(2):142. PubMed ID: 16197442
[No Abstract] [Full Text] [Related]
14. Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma.
Blanes M; González JD; Lahuerta JJ; Ribas P; Lorenzo I; Boluda B; Sanz MA; de la Rubia J
Leuk Lymphoma; 2015 Feb; 56(2):415-9. PubMed ID: 24828869
[TBL] [Abstract][Full Text] [Related]
15. Real world experience of bortezomib re-treatment for patients with multiple myeloma at first relapse.
Reyal Y; Popat R; Cheesman S; Rismani A; D'Sa S; Rabin N; Yong K
Br J Haematol; 2017 May; 177(3):495-497. PubMed ID: 27062387
[No Abstract] [Full Text] [Related]
16. A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma.
Rosenthal A; Kumar S; Hofmeister C; Laubach J; Vij R; Dueck A; Gano K; Stewart AK
Br J Haematol; 2016 Jul; 174(2):323-5. PubMed ID: 26403323
[No Abstract] [Full Text] [Related]
17. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
Palumbo A; Bringhen S; Rossi D; Cavalli M; Larocca A; Ria R; Offidani M; Patriarca F; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Morabito F; Grasso M; Leonardi G; Rizzo M; Falcone AP; Gottardi D; Montefusco V; Musto P; Petrucci MT; Ciccone G; Boccadoro M
J Clin Oncol; 2010 Dec; 28(34):5101-9. PubMed ID: 20940200
[TBL] [Abstract][Full Text] [Related]
18. [Sweet syndrome. Acute neutrophilic dermatosis in multiple myeloma].
Breier F; Hobisch G; Groz S
Hautarzt; 1993 Apr; 44(4):229-31. PubMed ID: 8482603
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Cakana A; van de Velde H; Richardson PG;
N Engl J Med; 2008 Aug; 359(9):906-17. PubMed ID: 18753647
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy.
Lee SE; Choi K; Han S; Lee J; Hong T; Park GJ; Yim DS; Min CK
Anticancer Drugs; 2017 Jul; 28(6):660-668. PubMed ID: 28430745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
